Tiroid nodüllerinde Bethesda sınıflandırması ve postoperatif patolojinin karşılaştırılması: Tek merkez sonuçları

Amaç: Güncel Amerikan Tiroid Derneği kılavuzu Bethesda sınıflandırmasında merkeze özel sonuçların bilinmesinin tiroid ince iğne aspirasyon biyopsisinin (İİAB) tanısal yeterliliğini artırmak için önemli olduğunu vurgulamaktadır. Bu çalışma Bethesda sınıflandırması ve postoperatif patoloji sonuçlarını kıyaslayarak her kategori için merkezimize özel kanser riskini ortaya konulmasını amaçlamaktadır. Yöntemler: Merkezimizde 2012-2018 yılları arasında tiroid nodülü nedeniyle ameliyat edilen hastaların ameliyat öncesi ve sonrası patoloji sonuçları geriye yönelik olarak incelendi. Bethesda sistemine göre sınıflandırılmış İİAB raporları olan hastalar çalışmaya dahil edildi. Ameliyat sonrası patolojiler incelenerek Bethesda sisteminin her kategorisi için ayrı ayrı kanser riskleri ortaya konuldu ve literatürle kıyaslandı. Bulgular: Çalışmaya 145 hasta dahil edildi. Ortalama yaş 45.9±13.6 idi. Bethesda sınıflandırmasına göre 3 (%2,1) hasta kategori I, 47 (%32,4) hasta kategori II, 16 (%11) hasta kategori III, 14 (%9,7) hasta kategori IV, 29 (%20) hasta kategori V ve 36 (%24,8) hasta kategori VI olarak raporlanmıştı. Ameliyat sonrası patoloji 66 (%45,5) hastada malignite ile uyumluydu. Malignite riski kategori I için %33,3, kategori II için %4,3, kategori III için %31,3, kategori IV için %42,9, kategori 5 için %62,1 ve kategori VI için %94,4 olarak hesaplandı. Sonuç: Sonuçlarımız Bethesda sistemi tarafından bildirilen malignite riskleriyle uyumluydu. Bethesda sınıflandırmasının doğrulanması ve ulusal adaptasyonun artırılması için daha geniş çalışmalara gereksinim vardır.

Comparison of the Bethesda system classification and postoperative cytology of thyroid nodules: A single center experience

Objective: Recent American Thyroid Association Guideline emphasizes that identifying the institutional malignancyrisks for each Bethesda category is mandatory to achieve more accurate preoperative diagnosis in thyroid nodules.Aim of this study is to compare the preoperative fine needle aspiration biopsy (FNAB) and postoperative pathologyresults in a single institution in the era of the Bethesda System for Reporting thyroid Cytology (TBSRTC).Methods: The data of the patients who underwent FNAB and thyroidectomy between 2012 and 2018 were collectedretrospectively. Patients who had available TBSRTC classification were included in the study. The malignancy risk ofeach TBSRTC classification was calculated.Results: One-hundred and forty-five patients were included. The mean age was 45.9±13.6. Preoperative FNABcategorization was TBSRTC I in 3 (2.1%) patients, TBSRTC II in 47 (32.4%) patients, TBSRTC III 16 (11%) patients,TBSRTC IV in 14 (9.7%) patients, TBSRTC V in 29 (20%) and VI in 36 (24.8%) patients. Postoperative pathologyrevealed malignancy in 66 (45.5%) of the patients. The malignancy risk was 33.3% in TBSRTC I, 4.3% in TBSRTC II,31.3% in TBSRTC III, 42.9% in TBSRTC IV, 62.1% in TBSRTC V and 94.4% in TBSRTC VI categories.Conclusion: Our results were conformable with the malignancy risks reported by TBSRTC. Larger studies should beperformed to validate and endorse nationwide standardization of the Bethesda system.

___

  • 1. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008; 22: 901-911. doi:10.1016/j.beem.2008.09.019.
  • 2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300. doi:10.3322/caac.20073.
  • 3. Yassa L, Cibas ES, Benson CB, et all. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007; 111: 508-516. doi:10.1002/cncr.23116.
  • 4. Bongiovanni, A. Spitale, W. C. Faquin, L. Mazzucchelli, and Z. W. Baloch, “The Bethesda system for reporting thyroid cytopathology: A meta-analysis,” Acta Cytologica. 2017; 61: 172.
  • 5. Patrizia S, Diana RE, Tommaso B, et all. A meta‐analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated? Cancer Cytopathol. 2015. doi:10.1002/cncy.21605.
  • 6. D. Ozdemir, N. Bestepe, S. Faki, et all. “Comparison of thyroid fine needle aspiration biopsy results before and after implementation of Bethesda classification,” Cytopathology, 2017 Oct; 28: 400-6.
  • 7. P. S. Sullivan, S. L. Hirschowitz, P. C. Fung, and S. K. Apple, “The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System,” Cancer Cytopathol., 2014 Dec; 122: 866-72.
  • 8. E. Machała, J. Sopiński, I. Iavorska, and K. Kołomecki, “Correlation of Fine Needle Aspiration Cytology of Thyroid Gland with Histopathological Results,” Polish J. Surg., vol. 90, no. 5, pp. 1–5, 2018.
  • 9. H. Her-Juing Wu, C. Rose, and T. M. Elsheikh, “The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy,” Diagn. Cytopathol., 2012 May; 40: 399-403.
  • 10. E. S. Cibas and S. Z. Ali, “The 2017 Bethesda System for Reporting Thyroid Cytopathology,” J. Am. Soc. Cytopathol., vol. 6, no. 6, pp. 217–222, 2017.
  • 11. R. L. Ferris, Z. Baloch, V. Bernet, et all. “American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making,” Thyroid, vol. 25, no. 7, pp. 760–768, 2015.
  • 12. B. Haugen, E. K. Alexander, K. C. Bible, et all, “2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer,” The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, 2016 Jan; 26: 1-133.
  • 13. Her-Juing Wu H, Rose C, Elsheikh TM. The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. DiagnCytopathol. 2012. doi:10.1002/dc.21754.
  • 14. Medina Chamorro FM, Calle JA, Stein JE, et all. Experience of the Implementation of Rapid On-Site Evaluation in Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. CurrProblDiagnRadiol. 2018; 47: 220-4. doi:10.1067/j.cpradiol.2017.06.009.
  • 15. Kim Y-Y, Han K, Kim E-K, et all. Validation of the 2015 American Thyroid Association Management Guidelines for Thyroid Nodules With Benign Cytologic Findings in the Era of the Bethesda System. Am J Roentgenol. 2018; 210: 629-34. doi:10.2214/AJR.17.18507.
  • 16. Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S. Implications of the proposed thyroid fine-needle aspiration category of “follicular lesion of undetermined significance”: A five-year multiinstitutional analysis. DiagnCytopathol. 2009; 37: 710-4. doi:10.1002/dc.21093.
  • 17. Isik A, Firat D, Yilmaz I et al. A survey of current approaches to thyroid nodules and thyroid operations. Int J Surg. 2018 Jun; 54(Pt A): 100-4. doi: 10.1016/j.ijsu.2018.04.037